» Articles » PMID: 32076044

Activated FGF2 Signaling Pathway in Tumor Vasculature is Essential for Acquired Resistance to Anti-VEGF Therapy

Overview
Journal Sci Rep
Specialty Science
Date 2020 Feb 21
PMID 32076044
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-vascular endothelial growth factor (VEGF) therapy shows antitumor activity against various types of solid cancers. Several resistance mechanisms against anti-VEGF therapy have been elucidated; however, little is known about the mechanisms by which the acquired resistance arises. Here, we developed new anti-VEGF therapy-resistant models driven by chronic expression of the mouse VEGFR2 extracellular domain fused with the human IgG4 fragment crystallizable (Fc) region (VEGFR2-Fc). In the VEGFR2-Fc-expressing resistant tumors, we demonstrated that the FGFR2 signaling pathway was activated, and pericytes expressing high levels of FGF2 were co-localized with endothelial cells. Lenvatinib, a multiple tyrosine kinase inhibitor including VEGFR and FGFR inhibition, showed marked antitumor activity against VEGFR2-Fc-expressing resistant tumors accompanied with a decrease in the area of tumor vessels and suppression of phospho-FGFR2 in tumors. Our findings reveal the key role that intercellular FGF2 signaling between pericytes and endothelial cells plays in maintaining the tumor vasculature in anti-VEGF therapy-resistant tumors.

Citing Articles

Lenvatinib enhances antitumor immunity of anti-PD-1 antibody.

Kato Y Int J Clin Oncol. 2025; .

PMID: 39985645 DOI: 10.1007/s10147-025-02721-5.


Reduction reactions dominate the interactions between Mg alloys and cells: Understanding the mechanisms.

Kim J, Gilbert J, Lv W, Du P, Pan H Bioact Mater. 2024; 45:363-387.

PMID: 39687558 PMC: 11647666. DOI: 10.1016/j.bioactmat.2024.11.020.


Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.

Mitea G, Schroder V, Iancu I, Miresan H, Iancu V, Bucur L Cancers (Basel). 2024; 16(21).

PMID: 39518052 PMC: 11545343. DOI: 10.3390/cancers16213612.


Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance.

Boichuk S, Dunaev P, Galembikova A, Valeeva E Cancers (Basel). 2024; 16(17).

PMID: 39272961 PMC: 11394061. DOI: 10.3390/cancers16173103.


Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer.

Lei X, Li Z, Huang M, Huang L, Huang Y, Lv S J Exp Clin Cancer Res. 2024; 43(1):83.

PMID: 38493151 PMC: 10944600. DOI: 10.1186/s13046-024-03003-0.


References
1.
Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

2.
Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

3.
Seghezzi G, Patel S, Ren C, Gualandris A, Pintucci G, Robbins E . Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998; 141(7):1659-73. PMC: 2132998. DOI: 10.1083/jcb.141.7.1659. View

4.
Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J . Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012; 122(6):1991-2005. PMC: 3366398. DOI: 10.1172/JCI58832. View

5.
Battegay E, Rupp J, Sage E, Pech M . PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994; 125(4):917-28. PMC: 2120083. DOI: 10.1083/jcb.125.4.917. View